IBJNews

Lilly wins FDA approval for Alzheimer's imaging agent

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. says it has won approval from the U.S. Food and Drug Administration for a new imaging agent that could help physicians better diagnose Alzheimer’s disease and other forms of dementia.

The agent, called Amyvid, is not expected to produce high-dollar sales for Lilly, but it could help to identify patients with Alzheimer’s—and those without it—earlier than other methods, perhaps improving treatment and focusing research efforts.

Indianapolis-based Lilly is currently studying an experimental treatment for Alzheimer’s disease, solanezumab, which if successful, could become a multibillion-per-year blockbuster and reverse Lilly’s recent struggles with expiring patents on its older blockbuster products. No treatment exists that slows or reverses the progression of Alzheimer's disease, which currently afflicts about 30 million people worldwide and is expected to afflict three times that number by 2050.

However, even Lilly officials say the chance of the solanezumab's success is low. That’s because scientists do not completely understand what causes Alzheimer’s disease. So efforts by Lilly and other major pharmaceutical companies to develop treatments is based so far on unproven theories.

Lilly’s scientists have followed the theory that Alzheimer’s is caused by the buildup of the protein beta-amyloid in a patient’s brain, which eventually forms sticky plaques that impede brain function. Solanezumab binds to amyloid in an effort to remove it from the brain via the bloodstream. And the imaging agent Amyvid binds to amyloid plaques, making them detectable using a PET scan.

Previously, the presence of amyloid plaques could only be confirmed by an autopsy, after a patient’s death. And sometimes the diagnosis of Alzheimer’s was proved wrong.

"It's estimated that one in five patients clinically diagnosed with probable Alzheimer's Disease during life do not end up having Alzheimer's Disease pathology upon autopsy," said Dr. Daniel Skovronsky, CEO of Avid Radiopharmaceuticals Inc., the company that developed Amyvid, and which Lilly acquired in 2010 for $300 million. "The approval of Amyvid offers physicians a tool that, in conjunction with other diagnostic evaluations, can provide information to help physicians evaluate their patients."

Amyvid will become available in limited supplies in June. The FDA approval comes more than a year after the agency was first scheduled to make a decision on the drug.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. These liberals are out of control. They want to drive our economy into the ground and double and triple our electric bills. Sierra Club, stay out of Indy!

  2. These activist liberal judges have gotten out of control. Thankfully we have a sensible supreme court that overturns their absurd rulings!

  3. Maybe they shouldn't be throwing money at the IRL or whatever they call it now. Probably should save that money for actual operations.

  4. For you central Indiana folks that don't know what a good pizza is, Aurelio's will take care of that. There are some good pizza places in central Indiana but nothing like this!!!

  5. I am troubled with this whole string of comments as I am not sure anyone pointed out that many of the "high paying" positions have been eliminated identified by asterisks as of fiscal year 2012. That indicates to me that the hospitals are making responsible yet difficult decisions and eliminating heavy paying positions. To make this more problematic, we have created a society of "entitlement" where individuals believe they should receive free services at no cost to them. I have yet to get a house repair done at no cost nor have I taken my car that is out of warranty for repair for free repair expecting the government to pay for it even though it is the second largest investment one makes in their life besides purchasing a home. Yet, we continue to hear verbal and aggressive abuse from the consumer who expects free services and have to reward them as a result of HCAHPS surveys which we have no influence over as it is 3rd party required by CMS. Peel the onion and get to the root of the problem...you will find that society has created the problem and our current political landscape and not the people who were fortunate to lead healthcare in the right direction before becoming distorted. As a side note, I had a friend sit in an ED in Canada for nearly two days prior to being evaluated and then finally...3 months later got a CT of the head. You pay for what you get...

ADVERTISEMENT